| Depression, Bipolar
Vraylar vs Latuda
Side-by-side clinical, coverage, and cost comparison for depression, bipolar.Deep comparison between: Vraylar vs Latuda with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLatuda has a higher rate of injection site reactions vs Vraylar based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Latuda but not Vraylar, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Vraylar
Latuda
At A Glance
Oral
Daily
Atypical antipsychotic
Oral
Once daily
Atypical antipsychotic
Indications
- Schizophrenia
- Manic Disorder
- Depression, Bipolar
- Major Depressive Disorder
- Schizophrenia
- Depression, Bipolar
Dosing
Schizophrenia Adults: start 1.5 mg once daily; recommended 1.5-6 mg once daily (max 6 mg). Pediatric patients (13-17 years): start 0.5 mg once daily; recommended 1.5-4.5 mg once daily (max 4.5 mg).
Manic Disorder Adults: start 1.5 mg once daily, increase to 3 mg on Day 2; recommended 3-6 mg once daily (max 6 mg). Pediatric patients (10-17 years): start 0.5 mg once daily; recommended 3 mg or 4.5 mg once daily (max 4.5 mg).
Depression, Bipolar Adults: start 1.5 mg once daily; may increase to 3 mg on Day 15 (max 3 mg once daily).
Major Depressive Disorder Adults (adjunctive to antidepressants): start 1.5 mg once daily; may increase to 3 mg on Day 15 (max 3 mg once daily).
Schizophrenia Adults: 40 mg once daily (range 40-160 mg/day); adolescents 13-17 years: 40 mg once daily (range 40-80 mg/day); take with food (at least 350 calories).
Depression, Bipolar Adults: 20 mg once daily as monotherapy or adjunctive therapy with lithium or valproate (range 20-120 mg/day); pediatric patients 10-17 years: 20 mg once daily as monotherapy (range 20-80 mg/day); take with food (at least 350 calories).
Contraindications
- History of hypersensitivity reaction to cariprazine, including rash, pruritus, urticaria, and reactions suggestive of angioedema (e.g., swollen tongue, lip swelling, face edema, pharyngeal edema, swelling face)
- Known hypersensitivity to lurasidone HCl or any components in the formulation
- Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil)
- Concomitant use with strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine)
Adverse Reactions
Most common (>=5%) Extrapyramidal symptoms, akathisia, nausea, restlessness, insomnia, somnolence, dyspepsia, vomiting
Serious Neuroleptic malignant syndrome, tardive dyskinesia, increased mortality in elderly patients with dementia-related psychosis, suicidal thoughts and behaviors, cerebrovascular adverse reactions, metabolic changes, leukopenia/neutropenia/agranulocytosis, orthostatic hypotension, seizures
Postmarketing Stevens-Johnson syndrome
Most common (>=5%) Somnolence, akathisia, extrapyramidal symptoms, nausea, vomiting, diarrhea, anxiety
Serious Neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, cerebrovascular adverse reactions, hyperprolactinemia, leukopenia/neutropenia/agranulocytosis, orthostatic hypotension and syncope, seizures, body temperature dysregulation
Postmarketing Urticaria, throat swelling, tongue swelling, dyspnea, rash, hyponatremia
Pharmacology
Cariprazine is an atypical antipsychotic that acts as a partial agonist at central dopamine D2/D3 and serotonin 5-HT1A receptors and as an antagonist at serotonin 5-HT2A receptors; its two major active metabolites, desmethylcariprazine (DCAR) and didesmethylcariprazine (DDCAR), have in vitro receptor binding profiles similar to the parent drug.
Lurasidone is an atypical antipsychotic that acts as an antagonist at dopamine D2 and serotonin 5-HT2A and 5-HT7 receptors and as a partial agonist at 5-HT1A receptors, with little affinity for histamine H1 or muscarinic M1 receptors; its efficacy in schizophrenia and bipolar depression may be mediated through combined D2 and 5-HT2A receptor antagonism.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Vraylar
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (5/12) · Qty limit (3/12)
Latuda
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (1/12)
UnitedHealthcare
Vraylar
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Latuda
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Vraylar
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Latuda
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$75/fillfill
Vraylar Savings Card - Non-covered benefitCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
VraylarView full Vraylar profile
LatudaView full Latuda profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.